OCT 21, 2018 10:22 PM PDT

New Technology Detects Early-Stage Lung Cancer

WRITTEN BY: Nouran Amin

image via European Pharmaceutical Review

According to recent research published in the Journal of Molecular Diagnostics, outcomes of patients with non-small-cell lung carcinoma (NSCLC) may be improved due to novel technology that is inexpensive and capable of high-throughput testing.

The new technology consists of an electric field-induced release and measurement (EFIRM) that can detect non-small-cell lung carcinoma (NSCLC) during the early stages when surgical interventions are possible. This is especially crucial since most NSCLC cases go undiagnosed until the advanced stages were interventions are challenging and fatality is high.

The highly sensitive and specific EFIRM technology will aim at detecting two epidermal growth factor receptor (EGFR) mutations that are implicated with lung cancer in the blood of NSCLC patients who have been diagnosed with the early stage of the disease. Additionally, the technology can monitor treatment and detect the recurrence in patients previously diagnosed with NSCLC.

Even though chemotherapy has improved, the survival rate for NSCLC patients is relatively poor due to the timing of the diagnosis.

"The revolutionary EFIRM technology is the most exciting development in the noninvasive liquid biopsy in recent years. The potential to detect early-stage lung cancer patients with an affordable blood or saliva test could save thousands to tens of thousands of lives annually worldwide," explains Charles M. Strom, MD, PhD, co-director of the Center for Oral/Head and Neck Oncology Research at the UCLA School of Dentistry.

Using EFIRM technology in early studies, patients had successfully measured two EGFR mutations derived from blood samples of patients with the late-stage NSCLC. During the present studies, the researchers investigated whether these mutations can be present in samples from patients with early-stage disease. "Currently, the clinical sensitivity of EFIRM to detect patients with NSCLC is limited by the percentage of tumors containing either or both of the two variants, which is estimated at 27 percent of NSCLC tumors," said co-investigator Wu-Chou Su, MD, of the Department of Internal Medicine, National Cheng Kung University Hospital and College of Medicine of the National Cheng Kung University, Tainan, Taiwan. "We are presently developing a 10-variant panel that contains detecting mutations expressed in 50 percent of all lung malignancies."

The researchers assure that the study does not provide evidence that the detection of EGFR mutations in the plasma of an individual is actually predictive that the patient has NSCLC. However, protective research may choose to explore the implications of EGFR mutations in lung cancer. As of now, EFIRM technology is useful for guiding treatment selection in patients where their biopsy material isn’t there. "We are gratified by the performance of the EFIRM platform in patients whose tumors were still small enough to qualify for surgical care. Work is underway to increase the number of mutations analyzed and to automate the process to increase sensitivity and facilitate mass screening," states Dr. Strom.

Source: ScienceDaily

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 06, 2019
Health & Medicine
DEC 06, 2019
Cell Phone Use Related Injuries on the Rise
Are you reading this on your cell phone? Check your posture and your surroundings! A study published yesterday in Jama Otolaryngology-Head & Neck Surge...
DEC 22, 2019
Clinical & Molecular DX
DEC 22, 2019
Can Google Health's AI interpret X-rays as well as radiologists?
Patients presenting with severe coughs, chest pain or suspected infections are more than likely to be sent for a chest X-ray -- the most commonly taken med...
DEC 23, 2019
Space & Astronomy
DEC 23, 2019
The Trouble With the InSight Mission's Burrowing Mole Explained
NASA’s InSight mission is designed to probe the red planet’s internal physical characteristics, including heat emanating from its core and Mars...
JAN 21, 2020
Space & Astronomy
JAN 21, 2020
Here's Why SpaceX Blew Up a Falcon 9 Rocket in Mid-Air
SpaceX completed a substantial milestone for NASA’s Commercial Crew Program this week, an undertaking that involved one of the commercial space compa...
JAN 28, 2020
Space & Astronomy
JAN 28, 2020
An Ambitious New Mission to Explore the Sun's Poles
A plethora of spacecraft have photographed the Sun, but every one of those photographs has been snapped from the rather limited perspective of the Sun&rsqu...
FEB 03, 2020
Technology
FEB 03, 2020
The Demand for Drone Delivery is High
Many consumers are demanding drones for delivery of their products. But how realistic is drone delivery? A study published in the INFORMS journal Transport...
Loading Comments...